Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone Oncology added, "We believe that a significant minority of patients with certain common cancers may have class I shared neoantigens, including up to approximately 10-15% in lung and colon cancer. Shared neoantigens are most prevalent in cancers driven by KRAS mutations, and many shared neoantigens are shared across indications. This has enabled us to design an off-the-shelf neoantigen-directed immunotherapy, SLATE, which is now in a Phase 1 clinical trial. These shared TSNA may also be used as targets for other immunotherapy approaches, such as bispecific antibodies or adoptive cell therapy. Importantly, through this work, we are developing a valuable intellectual property portfolio covering the use of these newly identified TSNA as part of neoantigen-targeted immunotherapy."